New hope: drug may shield breast cancer patients from dangerous side effect
NCT ID NCT07380646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether taking leucogen alongside standard ribociclib therapy can prevent severe neutropenia (dangerously low white blood cell counts) in women with early-stage hormone-positive breast cancer. About 94 participants will receive the combination and be monitored for four months. The goal is to see if leucogen can keep white blood cell levels safe, allowing patients to continue their cancer treatment without interruption.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
leucogen (a drug to boost white blood cell production)
What this could lead to
If it works, this could point toward a way to prevent dangerous drops in white blood cells during breast cancer treatment, allowing more patients to stay on their full therapy.
What could go wrong
This is a small, early-phase trial with only 94 participants and no comparison group, so results may not hold up in larger studies. The drug itself may cause side effects like bone pain or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast surgery department
RECRUITINGHangzhou, Zhejiang, 310058, China
Contact Phone: •••-•••-•••• Email: •••••@•••••